CG Oncology Inc. Common s... (CGON)
NASDAQ: CGON
· Real-Time Price · USD
27.76
0.82 (3.04%)
At close: May 01, 2025, 3:59 PM
27.42
-1.22%
After-hours: May 01, 2025, 07:43 PM EDT
Company Description
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CG Oncology Inc. Common stock
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Arthur Kuan |
Contact Details
Address: No Address available No city data available, Delaware United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001991792 |
| CUSIP Number | 156944100 |
| ISIN Number | US1569441009 |
| Employer ID | 37-1611499 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | Chairman & Chief Executive Officer |
| Ambaw Bellete M.S. | President & Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | 4 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |
| Apr 16, 2025 | 4 | Filing |